Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Non Operating Income (2020 - 2025)

Historic Non Operating Income for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $1.8 million.

  • Tango Therapeutics' Non Operating Income fell 5213.81% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 3986.31%. This contributed to the annual value of $15.5 million for FY2024, which is 2338.61% up from last year.
  • As of Q3 2025, Tango Therapeutics' Non Operating Income stood at $1.8 million, which was down 5213.81% from $2.1 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year Non Operating Income high stood at $4.4 million for Q1 2024, and its period low was -$81000.0 during Q4 2021.
  • For the 5-year period, Tango Therapeutics' Non Operating Income averaged around $2.0 million, with its median value being $2.1 million (2025).
  • As far as peak fluctuations go, Tango Therapeutics' Non Operating Income tumbled by 21095.89% in 2021, and later soared by 202345.68% in 2022.
  • Quarter analysis of 5 years shows Tango Therapeutics' Non Operating Income stood at -$81000.0 in 2021, then surged by 2023.46% to $1.6 million in 2022, then skyrocketed by 175.8% to $4.3 million in 2023, then fell by 23.46% to $3.3 million in 2024, then crashed by 45.21% to $1.8 million in 2025.
  • Its Non Operating Income was $1.8 million in Q3 2025, compared to $2.1 million in Q2 2025 and $2.7 million in Q1 2025.